Search results
3 days ago · Christian Angermayer invests in life sciences, fintech, AI, psychedelics and cryptocurrencies through his family office Apeiron Investment Group. He made his first millions cofounding biotech...
I am dedicated to fighting the global mental health crisis, both through atai Life Sciences, as well as through the mental health non-profit, Aurora.
Mar 1, 2018 · Christian Angermayer, a 39-year-old investor, in 1999 quit school to help found a biotech company that would eventually become Alnylam. When he sold the company, Angermayer used...
Christian Angermayer is a serial entrepreneur, investor, and founder of Apeiron Investment Group. Christian is the driving force behind the current renaissance of psychedelics - and the development of psilocybin and DMT as potential treatments for a wide range of mental health conditions.
Apeiron Investment Group is the private investment firm of entrepreneur and investor Christian Angermayer. We are global investors in the most exciting and world-changing tech & biotech companies with a hands-on, entrepreneurial approach.
Aug 1, 2020 · Christian Angermayer was paid by both sides in an intricate deal, where the reputation of the Japanese conglomerate as the world’s biggest tech investor helped to deflect allegations of...
Sep 15, 2021 · Christian Angermayer dropped out of college at 21 to co-found a biotech firm now worth $23 billion. The 43-year-old German billionaire runs his $3.5 billion family office Apeiron...
If you want to get in touch, please contact my team…. · Experience: Apeiron Investment Group · Location: London · 500+ connections on LinkedIn. View Christian Angermayer’s profile on...
Apeiron invests and builds companies in Life Sciences, Fintech & Crypto, Future Tech, and Experiences, Natural Resources & Clean Energy, Hospitality & Happiness. In all of these sectors, we have deep experience and a proven track record over 20 years.
Dec 15, 2021 · German entrepreneur Christian Angermayer says he will hold onto his stake in Atai Life Sciences NV for another two years despite a dismal six months as a publicly traded company that saw the...
